Stay updated with breaking news from Rob Iannone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings,...
As zanidatamab awaits an FDA decision, Jazz is sharing long-term phase 2 data in advanced biliary tract cancer for the HER2-targeted bispecific antibody.
Zanidatamab has received priority review from the FDA for the treatment of patients with HER2-positive metastatic biliary tract cancer.
Zanidatamab is a HER2-targeted bispecific antibody that can simultaneously bind 2 non-overlapping epitopes of the HER2 receptor.
Jazz Pharmaceuticals announced it will present one oral presentation and four poster presentations on narcolepsy and idiopathic hypersomnia.